Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biosearch S A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and 1 distinct art unit, reflecting a focused area of activity for the company. This concentration indicates that the company's immediate legal efforts are dedicated to a specific biological or pharmaceutical innovation. The pending office action is the only active matter currently being reviewed by the patent office for this company.
The busiest examiner for the portfolio is GANGLE, BRIAN J, who handles 1 busiest examiner pending office action. With 1 pending office action active, the company's current prosecution trajectory is defined by the requirements of this examiner. For a practitioner, it is essential to understand the examiner's previous actions and technical requirements within the Biotechnology & Pharmaceuticals field. The success of the pending office action will be the primary factor in the company's near-term intellectual property growth. Effectively addressing the concerns of this specific examiner is the most important step for the company's current prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18009241 | PROBIOTIC FOR THE TREATMENT OF INFERTILITY AND RECURRENT PREGNANCY LOSS | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18009241 | PROBIOTIC FOR THE TREATMENT OF INFERTILITY AND RECURRENT PREGNANCY LOSS | GANGLE, BRIAN J | 1645 | §102 | Final Rejection | — | Pending | Dec 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial